Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing

Vascular Disorders: Heart & Legs

Peripheral Artery Disease (PAD):  

Pre-clinical animal efficacy and toxicity studies to support an IND application to the US FDA for this indication have also been completed and a filing is anticipated in 9-12 months.


Zhittya Current Active Drug Development Programs:

Developing healthier lives for the world


For more information contact us today

Stroke: A number of independent  efficacy studies in  animal models of stroke have been completed and support the potential of FGF-1 to be of benefit for stroke. Zhittya will now initiate animal toxicity studies to support an IND application.


Vascular Dementia: This condition is also referred as “multi-infarct dementia” and develops over a period of time after a person suffers numerous mini-strokes. This chronic lack of blood perfusion results in a gradual loss of neurons in the brain and dementia. As FGF-1 can cross the blood brain barrier, IV infusions of the drug will be examined to see if this treatment can help reverse the dementia by bringing additional blood perfusion to the brain in animal models of vascular dementia.    

Alzheimer’s Disease: ​Very recent work has indicated that one of the first steps in the development of Alzheimer’s Disease is a degeneration in the microvasculature of the brain. This decrease in brain perfusion precedes the classical symptoms of this disease including memory loss, plaque deposition outside of nerve cells and “neurofibrillary tangles” within neurons. Pre-clinical work in animal models of Alzheimer Disease will be initiated to see if therapeutic angiogenesis in the brain can delay or reverse the course of this disease.

Coronary Artery Disease: ​Pre-clinical animal efficacy and toxicity studies to support an IND application to the US FDA have been completed.  Submission of the IND application is expected within the next 6 months.

Wound Healing Disorders

Vascular Disorders In the Brain

Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing

Zhittya currently has eight active drug development programs utilizing different formulations of FGF-1 to treat the following medical indications.​​ Zhittya has contracted with a cGMP biologics drug manufacturer to produce clinical and preclinical lots of its drug products to support these programs. 

Diabetic foot ulcers: Pre-clinical animal efficacy and toxicity studies to support an IND (Investigational New Drug) application to the US FDA have been completed. A Phase I Clinical Protocol has been developed and a clinical trial site in the Las Vegas area has been identified. An IND submission is planned in the near future.


Venous leg ulcers: This program is at a similar stage of development as the diabetic foot ulcer program and an IND submission is planned to occur after the IND for the diabetic foot ulcers application has been filed.